Weekly Digest - October 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - October 2024
8 Oct 2024: FDA gives Adcendo green light to trial ADC in Phase I/II sarcoma study
- Adcendo’s ADC candidate, ADCE-D01, received IND clearance from the US FDA and will enter a Phase I/II study, known as the ADCElerate-01 trial, as a monotherapy for patients with metastatic and unresectable soft tissue sarcoma (STS)
- ADCE-D01 targets the endocytic receptor uPARAP (Endo180), which is overexpressed in multiple STS subtypes
- Adcendo recently secured a deal potentially worth over $1 billion with China-based Multitude for its ADC candidate ADCE-T02 and completed an €82 million ($89.6 million) Series A funding round to advance its ADC pipeline
- In 2023, Adcendo concluded an $89.6m Series A funding round to develop its ADC pipeline and entered a deal with Duality Biologics, granting it a licence to Duality’s Duality Immune Toxin Antibody Conjugates (DITAC) linker/payload platform for its lead uPARAP-ADC mesenchymal cancers programme
